« Back to Covid-19 Home Page

COVID-19 clinical support

The current category is Managing Co-morbidities during Covid-19 pandemic

Medications

Palliative care medicines: see Palliative care section

Priority patients that will gain most benefit:

  • at risk of a serious adverse drug event that can be identified through monitoring
  • taking a Narrow Therapeutic Index drug during a phase when intensive monitoring is still required (e.g. upon initiation)
  • have recently had an illness that may have impacted on how their drug works

Structured Medication Review

Structured Medication Review for Diabetes Webinar – 19 August 2020

Mental health structured medication review webinar – 13 August 2020

Structured Medication Review for heart failure and hypertension webinar – 11 August 2020

ACEi/ARBs

MHRA: no concern with COVID. Do not stop

Anticoagulation

BP

During infection: assess on case by case basis if hypotensive.

Chloroquine and hydroxychloroquine

Controlled Drugs

Dermatology

EPS

Roll out of Electronic Prescription Service (EPS) Phase 4

To help you prepare for winter, NHSE are accelerating deployment of EPS Phase 4 allowing patients without a nominated pharmacy to use EPS

Heart-Failure

Illicit drugs

The supply of illicit drugs into the UK has reduced significantly and will continue to reduce further. The result of this is that street prices of illicit drugs are rising, and their quality is diminishing. The illicit trade in prescription medication such as diazepam and pregabalin is increasing with reports that prices have already doubled.

To prevent the levels of theft that are likely to seriously affect operational effectiveness and the safety of all staff at this most critical time, organisations should urgently review their current security arrangements.

Inhalers

Asthma patients should continue inhalers and medication as normal.

Multi Compartment Aids

NSAIDS

Pharmacological management of Adult non-cancer chronic pain

Rheumatology

Shortages